Cox proportional hazards model for diagnosis of NHL within the entire study population and in the group of patients who have initiated HAART (post-HAART)
| . | Entire study population . | Post-HAART . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Multivariate . | Multivariate including pVL . | |||||||||
| RH . | 95% CI . | P . | RH . | 95% CI . | P . | RH . | 95% CI . | P . | RH . | 95% CI . | P . | |
| Sex (female vs male) | 0.73 | 0.51 -1.04 | .08 | 0.63 | 0.39 -1.03 | .07 | 0.35 | 0.15 -0.80 | .0127 | 0.33 | 0.13 -0.85 | .021 |
| Ethnicity (white vs nonwhite) | 0.64 | 0.39 -1.05 | .08 | 0.59 | 0.27 -1.27 | .18 | 0.68 | 0.25 -2.12 | .48 | 1.33 | 0.44 -3.43 | .69 |
| AIDS (td, yes vs no) | 3.61 | 2.59 -5.04 | < .001 | 1.48 | 0.99 -2.21 | .05 | 1.01 | 0.51 -2.02 | .98 | 0.87 | 0.39 -1.95 | .73 |
| Age (per 10 years older) | 1.25 | 1.10 -1.42 | < .001 | 1.32 | 1.13 -1.55 | < .001 | 1.43 | 1.14 -1.79 | .002 | 1.52 | 1.19 -1.95 | < .001 |
| Nadir CD4 cell count (td, per 50% lower) | 1.25 | 1.20 -1.30 | < .001 | 1.01 | 0.93 -1.10 | .79 | 0.95 | 0.83 -1.09 | .46 | 0.96 | 0.82 -1.11 | .56 |
| Latest CD4 cell count (td, per 50% lower) | 1.53 | 1.46 -1.60 | < .001 | 1.44 | 1.32 -1.59 | < .001 | 1.57 | 1.34 -1.83 | < .001 | 1.39 | 1.13 -1.69 | .001 |
| Latest haemoglobin (td, per 1 g/dL lower) | 1.23 | 1.14 -1.33 | < .001 | 1.06 | 0.97 -1.16 | .20 | 1.09 | 0.95 -1.25 | .20 | 1.15 | 0.99 -1.34 | .07 |
| Weight (td, per 5 kg lower) | 1.09 | 1.02 -1.15 | .006 | 1.05 | 0.97 -1.13 | .20 | 1.09 | 0.97 -1.22 | .16 | 1.05 | 0.93 -1.19 | .41 |
| Latest plasma viral load (td, per 1 log10 copies/mL higher)4-150 | 1.71 | 1.47 -1.99 | < .001 | — | — | — | — | — | — | 1.51 | 1.21 -1.88 | < .001 |
| Initiation of HAART (> June 1997 vs ≤ June 1997)4-150 | 0.41 | 0.21 -0.79 | .008 | — | — | — | 0.53 | 0.23 -1.24 | .14 | 0.71 | 0.30 -1.68 | .44 |
| . | Entire study population . | Post-HAART . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Multivariate . | Multivariate including pVL . | |||||||||
| RH . | 95% CI . | P . | RH . | 95% CI . | P . | RH . | 95% CI . | P . | RH . | 95% CI . | P . | |
| Sex (female vs male) | 0.73 | 0.51 -1.04 | .08 | 0.63 | 0.39 -1.03 | .07 | 0.35 | 0.15 -0.80 | .0127 | 0.33 | 0.13 -0.85 | .021 |
| Ethnicity (white vs nonwhite) | 0.64 | 0.39 -1.05 | .08 | 0.59 | 0.27 -1.27 | .18 | 0.68 | 0.25 -2.12 | .48 | 1.33 | 0.44 -3.43 | .69 |
| AIDS (td, yes vs no) | 3.61 | 2.59 -5.04 | < .001 | 1.48 | 0.99 -2.21 | .05 | 1.01 | 0.51 -2.02 | .98 | 0.87 | 0.39 -1.95 | .73 |
| Age (per 10 years older) | 1.25 | 1.10 -1.42 | < .001 | 1.32 | 1.13 -1.55 | < .001 | 1.43 | 1.14 -1.79 | .002 | 1.52 | 1.19 -1.95 | < .001 |
| Nadir CD4 cell count (td, per 50% lower) | 1.25 | 1.20 -1.30 | < .001 | 1.01 | 0.93 -1.10 | .79 | 0.95 | 0.83 -1.09 | .46 | 0.96 | 0.82 -1.11 | .56 |
| Latest CD4 cell count (td, per 50% lower) | 1.53 | 1.46 -1.60 | < .001 | 1.44 | 1.32 -1.59 | < .001 | 1.57 | 1.34 -1.83 | < .001 | 1.39 | 1.13 -1.69 | .001 |
| Latest haemoglobin (td, per 1 g/dL lower) | 1.23 | 1.14 -1.33 | < .001 | 1.06 | 0.97 -1.16 | .20 | 1.09 | 0.95 -1.25 | .20 | 1.15 | 0.99 -1.34 | .07 |
| Weight (td, per 5 kg lower) | 1.09 | 1.02 -1.15 | .006 | 1.05 | 0.97 -1.13 | .20 | 1.09 | 0.97 -1.22 | .16 | 1.05 | 0.93 -1.19 | .41 |
| Latest plasma viral load (td, per 1 log10 copies/mL higher)4-150 | 1.71 | 1.47 -1.99 | < .001 | — | — | — | — | — | — | 1.51 | 1.21 -1.88 | < .001 |
| Initiation of HAART (> June 1997 vs ≤ June 1997)4-150 | 0.41 | 0.21 -0.79 | .008 | — | — | — | 0.53 | 0.23 -1.24 | .14 | 0.71 | 0.30 -1.68 | .44 |
The multivariate models also included adjustment for present and previous use of individual antiretroviral drugs (if P≤.10 in an unadjusted analysis for the entire population).
RH indicates relative hazard; CI, confidence interval; td, time-dependent.
Univariate model restricted to patients starting HAART.